BioAlliance Pharma SA (Euronext Paris – BIO), a Company dedicated to orphan oncology products and specialty products, announces that its Shareholders’ meeting was held today at its headquarters and has adopted all the resolutions supported by its Board of Directors.
Among other decisions, the Shareholders’ meeting has appointed Thomas Hofstaetter as independent Board Member, increasing thus the number of independent members to 5 out of a total of 8.
With a Ph.D. Degree in Biochemistry and Molecular Biology, Thomas Hofstaetter has conducted an international career in Germany, in the United States and in Japan, within international groups (Wyeth, Aventis…) where he hold strategic positions at the highest level in external growth and business development. For the last two years and until December 2011, he has been CEO of VaxInnate Corporation and he is today board member of another American biotech company, Geron Corporation.
« We are delighted to have Thomas Hofstaetter joining our Board. His appointment is in line with the Board’s ongoing strategy to involve international profiles. Thomas’ experience and expertise in business/corporate development will be particularly important to support BioAlliance’ future strategic initiatives”, declares Judith Greciet, CEO of BioAlliance Pharma.
Besides, due to internal organization changes, ING Belgium, represented by Luc Van de Steen, has announced at the last Board meeting of BioAlliance Pharma its wish to resign from its Board member mandate.
“I wish to thank ING Belgium for its support and its confidence as BioAlliance’ shareholder and Luc Van de Steen for his constant involvement in our Board”, declares Patrick Langlois, Chairman of BioAlliance Board of Directors. “I am happy to welcome Thomas Hofstaetter who, together with the other Board’s members, will do his best to bring his expertise and his know-how to the Company in the objective of a strong growth”.
As of today, BioAlliance Pharma’s Board of Directors is composed of:
- Patrick Langlois, Chairman of the Board of Directors and independent Board Member
- Judith Greciet, Chief Executive Officer and Board Member
- Michel Arié, independent Board Member
- Catherine Dunand, independent Board Member
- Thomas Hofstaetter, independent Board Member
- David H. Solomon, independent Board Member
- Financière de la Montagne, represented by Nicolas Trebouta, Board Member
- Kurma Life Sciences Partners, represented by Rémi Droller, Board Member
Voting results of the Combined Shareholders Meeting are available on our website at www.onxeo.com, section Investors/Shareholders’ meeting.